Renal cancer drug temsirolimus shows promise against mesothelioma

May 1, 2011 in Cancer

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

Temsirolimus, a kinase inhibitor, blocks the action of mammalian target of rapamycin (mTOR), a protein that regulates cell growth, which can slow tumor growth. It's used to treat advanced .

But researchers in Austria have found that temsirolimus also may slow the growth of malignant pleural mesothelioma cells. Mesothelioma, a that is usually caused by exposure to asbestos and may not appear until 30 to 50 years after exposure, frequently resists and .

The researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic, or growth-stopping, effect on all mesothelioma cells. However, mesothelioma cells that were resistant to cisplatin, a widely used chemotherapy drug, showed hypersensitivity against temsirolimus.

That suggests that mTOR inhibitors like temsirolimus might be a promising treatment strategy either in combination with chemotherapy or as second-line treatment after chemotherapy failure.

"Malignant mesothelioma is a severe human malignancy characterized by a very bad prognosis, with a mean patient survival time of less than one year," said Professor Walter Berger, PhD, of the Institute of Cancer Research at the Medical University of Vienna. "This unacceptable situation is mainly caused by late diagnosis combined with a distinct resistance to all forms of systemic therapy available so far. Mesothelioma is frequently caused by asbestos exposure and unfortunately -- based on the long latency period -- the incidence peak lies, despite the ban on asbestos, still ahead. Consequently, novel therapeutic options for this devastative disease are urgently needed.

"In our preclinical study, published in the JTO, we were able to demonstrate that inhibition of the major oncogene mTOR is active against human mesothelioma especially after development of chemotherapy resistance both in vitro and in vivo," Berger said. "These results suggest the initiation of clinical trials involving mTOR inhibitors as a novel anti-mesothelioma strategy."

Provided by International Association for the Study of Lung Cancer

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts
  • A question about drug tolerance
    created12 hours ago
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • portable metabolism meter?
    createdMay 21, 2012
  • Rare medical conditions on 20/20 tonight
    createdMay 18, 2012
  • "Good" Cholesterol in Doubt
    createdMay 17, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Cancer docs often deal with own grief, doubts when patients die

(HealthDay) -- Some cancer doctors may build up emotional walls -- distancing themselves from the patients they can't save -- to avoid grief, sadness and even despair, new research shows.

Cancer created 17 hours ago | popularity not rated yet | comments 0 | with audio podcast

Regorafenib active in metastatic GI stromal tumors

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, ...

Cancer created 17 hours ago | popularity not rated yet | comments 0

Robotic-assisted prostate cancer surgery drives up costs

In one of the most comprehensive analyses to date of the cost of robotic-assisted, laparoscopic surgery for prostate cancer, researchers at UPMC found that this now-dominant surgical approach is significantly more costly ...

Cancer created 19 hours ago | popularity not rated yet | comments 0

Cardio fitness levels of breast cancer patients may affect survival

Women receiving care for breast cancer have significantly impaired cardio-pulmonary function that can persist for years after they have completed treatment, according to a study led by scientists at Duke University Medical ...

Cancer created 19 hours ago | popularity not rated yet | comments 0 | with audio podcast

Breast MRI helps predict chemotherapy's effectiveness

Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy significantly earlier than possible through clinical examination, according to a new study published online ...

Cancer created May 23, 2012 | popularity not rated yet | comments 0


No new neurons in the human olfactory bulb

(Medical Xpress) -- Research from Karolinska Institutet shows that the human olfactory bulb - a structure in the brain that processes sensory input from the nose - differs from that of other mammals in that no new neurons ...

Spatial configuration can spark deja vu, psychology study reveals

(Medical Xpress) -- Déjà vu - that strange feeling of having experienced something before - is more likely to occur when a scene's spatial layout resembles one in memory, according to groundbreaking new research ...

A revealing hand

What did you have for lunch yesterday? How many times a month do you eat nuts? How about your kids -- how many servings of vegetables did they consume today?

World's biggest stroke clot-buster trial reveals patient benefits

(Medical Xpress) -- Patients given a clot-busting drug within six hours of a stroke are more likely to make a better recovery than those who do not receive the treatment, new research has found.

Mums-to-be missing out on benefits of water immersion

Queensland mums-to-be are being denied access to water immersion during labour even though research shows it shortens labour and reduces interventions.

Expert: Medicaid cuts will hurt low-, middle-income Illinois seniors

(Medical Xpress) -- Springfield’s plan to slash nearly $1.4 billion from the state’s Medicaid program will ultimately result in bigger medical (and financial) problems for low- and middle-income ...